Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years

Figure 2

Survival function showing time to protocol deviation. Time to first deviations due to all reasons (A), due to toxicity (B), due to comorbidity (C), due to patient related factors (D) and due to physician related factors (E). Censoring of observation has occurred at either 52, 104 or 156 weeks of therapy. The overall median survival cannot be computed for toxicity and comorbidity as survival exceeds 50% at the end of the study. DAS28, disease activity score in 28 joints.

Back to article page